Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue
📧 Sign up to get email alerts when something new happens for Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 clinical trial update evaluating zanubrutinib in combination with sonrotoclax for relapsed or refractory B-cell non-Hodgkin lymphoma…
-
CLINICAL_TRIALS trial_result · 2026-03-05Clinical Trial Update: Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial evaluating ixazomib citrate with rituximab in indolent B-cell non-Hodgkin lymphoma has posted results.
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas [Phase 2]
Phase 2 trial evaluating frontline obinutuzumab and ibrutinib in indolent non-Hodgkin lymphoma is active but not recruiting, per ClinicalTri…
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. [Phase 1]
Phase 1 study evaluating T cells engineered to co-express kappa and CD28 CARs for relapsed/refractory kappa+ non-Hodgkin lymphoma and chroni…
-
CLINICAL_TRIALS trial_result · 2025-10-28Clinical Trial Update: Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) [Phase 2]
Phase 2 clinical trial update for epcoritamab in newly diagnosed marginal zone lymphoma, currently recruiting across MZL subtypes.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-03-21Clinical Trial Update: Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas [Phase 2]
Phase 2 trial of pembrolizumab alone or with idelalisib or ibrutinib in relapsed/refractory chronic lymphocytic leukemia or various low-grad…
-
CLINICAL_TRIALS trial_result · 2022-03-02Clinical Trial Update: Radiation Therapy Alone for the Treatment of Stage 1 and 2 Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma [Phase 2]
Phase 2 trial evaluating radiation therapy alone for Stage 1 and 2 MALT lymphoma shows completed status with results posted.
-
CLINICAL_TRIALS trial_result · 2018-04-11Clinical Trial Update: Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma [Phase 1]
Phase 1 study evaluating alisertib in combination with vorinostat in adults with relapsed or recurrent Hodgkin lymphoma, B-cell non-Hodgkin …
-
CLINICAL_TRIALS trial_result · 2018-03-06Clinical Trial Update: Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating vorinostat in multiple low-grade non-Hodgkin lymphomas, including MALT lymphoma, nodal marginal zone lymphoma, foll…
-
CLINICAL_TRIALS trial_result · 2015-01-27Clinical Trial Update: Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating rituximab, cyclophosphamide, bortezomib, and dexamethasone in relapsed/refractory low-grade follicular lym…
-
CLINICAL_TRIALS trial_result · 2014-12-23Clinical Trial Update: Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms [Phase 1]
A Phase 1 trial evaluating the combination of bortezomib and flavopiridol in patients with recurrent or refractory indolent B-cell neoplasms…
-
CLINICAL_TRIALS trial_result · 2011-12-07Clinical Trial Update: Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma [Phase 2]
Phase 2 clinical trial evaluating tipifarnib in relapsed or refractory lymphoma has completed with results posted in 2011.